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Aims Chronic right ventricular (RV) pacing may impose ventricular dyssynchrony leading to LV remodelling and is associ-
ated with increased morbidity and mortality. Upgrading patients with chronic RV pacing to cardiac resynchronization
therapy (CRT) may be considered to restore synchronicity and prevent these deleterious effects.
Methods
and results
A total of 172 patients from two tertiary centres were analysed over a mean follow-up of 21.7 and 23.5 months after
primary CRT implantation (n ¼ 102) and CRT upgrade (n ¼ 70), respectively. In the latter group, mean duration of
RV pacing before CRT upgrade was 80.3 months, and ventricular stimulation was .95%. A significant improvement in
left ventricular (LV) ejection fraction (10 and 11% absolute increase in primary CRT vs. upgrades, respectively),
LV end-diastolic diameter index (20.15 cm/m2 vs. 20.2 cm/m2), and LV end-systolic diameter (26.0 vs.
27.0 mm) was observed in both groups, which did not differ between primary CRT recipients and CRT upgrades.
Response to CRT upgrade was independent of the underlying rhythm, QRS duration, duration of prior RV pacing, or
LV function and size at baseline. Of note, even seven of nine patients with RV pacing .12 years responded favourably
to CRT.
Conclusion The current study demonstrates that CRT reverses LV remodelling in heart failure patients with chronic RV pacing in
a similar way as in primary CRT recipients, even after very long periods of RV pacing. Our data, therefore, may have
important implications for the treatment of pacemaker-dependent patients with heart failure, and support the use of
CRT in this setting.
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Introduction
Biventricular pacing (cardiac resynchronization therapy, CRT) has
been shown to reduce morbidity and mortality in heart failure
patients with a left ventricular (LV) ejection fraction (LVEF)
,35% and a wide QRS complex (.120 ms).1–3 In these patients,
LV function is impaired as a result of asynchronous contractions of
the different segments within the left ventricle as well as between
the right and left ventricle. Concomitant pacing with a coronary
sinus lead implanted in a lateral or posterolateral vein resynchro-
nizes the contraction, resulting in reverse LV remodelling with a
decrease in LV size and an increase in LVEF.4–6 The extent of
LV reverse remodelling is of crucial importance, as it directly
relates to the long-term prognosis after CRT.7,8
Right ventricular (RV) apical pacing by a permanent pacemaker is
the standard treatment for patients with severe bradyarrhythmias.
However, RV pacing (like left bundle branch block) leads to a
delayed activation of lateral LV segments resulting in intra- and
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Table 1 Baseline parameters
Characteristic Primary CRT CRT upgrade P-value
Patients (n, %) 102/172 (59.3) 70/172 (40.7)
Demographics
Age at implantation (years) 61.0 (54–67)a 66.5 (57.0–75.0)a 0.005
Male (n, %) 82 (80.4) 51 (72.9) 0.25
Underlying heart disease (n, %) 0.74
Ischaemic cardiomyopathy 41 (40.2) 36 (51.4)
Non-ischaemic cardiomyopathy 61 (59.8) 34 (48.6)
Duration of right ventricular pacing (months) 60.0 (43.8–96.0)
Average ventricular stimulation (% of time) 99 (90–100)
NYHA class (n, %) 0.2
I 0 0
II 20 (20) 20 (29)
III 76 (75) 48 (69)
IV 5 (5) 2 (3)
Echocardiographic baseline parameters
LV ejection fraction (%) 20.0 (16.8–29.0) 24.0 (17.8–30.0) 0.12
End-diastolic volume (mL)b 244 (175–305) 219 (141–259) 0.07
End-diastolic volume index (mL/m2)b 120 (92–144) 104 (82–134) 0.15
End-systolic volume (mL)b 183 (134–252) 164 (95–217) 0.12
End-systolic volume index (mL/m2)b 92.2 (66.9–115) 83.1 (53.8–111) 0.18
LV end-diastolic diameter (mm) 70.0 (60.0–78.8)a 64.0 (57.5–71.0)a 0.008
LV end-diastolic diameter index (cm/m2) 3.5 (3.0–3.9) 3.2 (3.0–3.6) 0.03
LV end-systolic diameter (mm) 60.0 (52.0–69.0)a 54.5 (46.0–62.0)a 0.002
Left ventricular muscle mass index (g/m2)b 165 (150–194) 149 (109–201) 0.48
Pulmonary artery pressure (mmHg) 34.5 (25.0–40.8) 31.0 (23.3–38.8) 0.46
Left atrium index (cm/m2) 2.4 (2.2–2.8) 2.6 (2.2–3.1) 0.35
Degree of mitral regurgitation (n, %) 0.31
Mild 73 (74) 41 (66)
Moderate 18 (18) 14 (23)
Severe 8 (8) 7 (11)
Rhythm at time of implantation
Sinus rhythm/VAT pacing 70 (68.6) 33 (47.1) 0.005
Atrial fibrillation (n, %) 32 (31.4) 37 (52.9) 0.005
QRS width (ms) 154 (133–178)a 184 (163–205)a ,0.001
Pharmacologic therapy at time of implantation (n, %)
Beta-blockers 91 (89.2) 63 (90) 0.87
ACE-inhibitors 77 (75.5) 45 (64.3) 0.11
AT receptor blockers 20 (19.6) 22 (31.4) 0.08
Diuretics 84 (82.4) 49 (70.0) 0.09
Aldosterone antagonists 53 (52) 33 (47.1) 0.54
Aspirin 58 (56.9) 36 (51.4) 0.49
Oral anticoagulation 43 (42.2) 41 (58.6) 0.03
Number of patients (%) and median (25–75 percentile) are shown for categorical and continuous data, respectively. AF, atrial fibrillation; ACE, angiotensin converting enzyme; AT,
angiotensin; CRT, cardiac resynchronization therapy; LV, left ventricular; NYHA, New York Heart Association.
aNot normally distributed.
bn ¼ 69.
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interventricular dyssynchrony. As such, chronic RV pacing has been
shown to induce LV remodelling, impair LV function, and increase
the severity of mitral regurgitation.9–12 As a result, long-term RV
pacing may be deleterious and has been associated with increased
morbidity and mortality.13,14 ‘Upgrading’ these patients to CRT
therefore intuitively appears reasonable to correct dyssynchrony.
Previous studies examining the effect of biventricular pacing on
LV remodelling, however, were limited due to small patient
numbers and relatively short follow-up periods.15–18 The current
study was hence designed to assess the long-term effect of CRT
on reverse LV remodelling in a large cohort of heart failure patients
upgraded to CRT after chronic RV pacing, and compare it with that
observed after primary CRT implantation.
Methods
Study population
We retrospectively reviewed 69 consecutive patients at the University
Hospital of Zurich and 103 consecutive patients at Ohio State Univer-
sity, who underwent either primary CRT implantation or CRT upgrade
between 2001 and 2008, and for whom echocardiographic follow-up
data at least 6 months after CRT implantation were available. At the
time of implantation, patients were managed by a heart failure special-
ist and were on optimal medical heart failure therapy including a beta-
blocker as well as an angiotensin converting enzyme inhibitor or an
angiotensin receptor blocker (unless contraindicated or not tolerated,
Table 1).
Cardiac resynchronization therapy upgrade recipients had a pace-
maker implanted for a standard bradycardia indication or after atrio-
ventricular (AV) node ablation for refractory atrial fibrillation. Mean
duration of RV pacing before the upgrade procedure was 80.3
months; average percent of ventricular stimulation had to be in
excess of 50% for at least 6 months for a patient to be included
(Table 1). Patients were selected for CRT implantation based on
current standard criteria and guidelines.19
Echocardiography
Only subjects in whom echocardiographic follow-up data were avail-
able were included in the study. Patients underwent baseline echocar-
diography before the implantation procedure and at least 6 months
thereafter. Standard parameters including LVEF (as assessed by
biplane Simpson’s rule in apical four- and two-chamber view), LV end-
diastolic diameter and LV end-diastolic diameter index, LV end-systolic
diameter, left atrial index, the degree of mitral regurgitation (as
recorded on a semi-quantitative scale), and pulmonary artery pressure
(as estimated from tricuspid regurgitation using CW-Doppler) were
recorded whenever available. Patients demonstrating an absolute
increase in LVEF of at least 10% at follow-up were considered respon-
ders to CRT.
Biventricular pacemaker implantation
Biventricular pacemaker implantation was performed following stan-
dard protocols, using either a left or right cephalic or subclavian
venous access. Retrograde venous angiography was performed to
facilitate optimal positioning of the LV lead into the coronary sinus.
The LV lead was preferably implanted in the lateral or postero-lateral
mid-ventricular region of the left ventricle whenever possible.
Figure 1 Response to CRT in primary and CRT upgrade recipi-
ents. A significant improvement in left ventricular ejection fraction
(LVEF, A), left ventricular end-diastolic diameter (LVEDD, B), and
left ventricular end-systolic diameter (LVESD, C) was observed
both after primary CRT implantation and after CRT upgrades.
*P, 0.0001 vs. baseline in primary CRT group or in CRT upgrade
group, **P ¼ 0.001 vs. baseline in primary CRT group. ‘Pre’ and
‘Post’ denote values before and afterCRT implantation, respectively.
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Statistics
Comparison of categorical variables was performed by x2 and Fisher’s
exact test (in case of low sample sizes). The influence of the aetiology
of heart failure, underlying heart rhythm, QRS width, and duration of
preceding RV pacing on CRT response rate was assessed using
Pearson’s x2 test. Continuous variables within the same group (i.e.
comparison of variables before and after CRT implantation) were
analysed by two-sided paired Student’s t-test (for normally distributed
variables) or Wilcoxon signed-rank test (for non-normally distributed
variables). Continuous variables between groups (i.e. comparison
between primary CRT implantation and CRT upgrade) were analysed
by unpaired two-sided Student’s t-test (for normally distributed
variables) or Mann–Whitney U test (for non-normally distributed vari-
ables). Confidence intervals were calculated using the t-test. A
P-value , 0.05 was considered significant. Statistical analysis was per-
formed using SPSS Ver 17.0 (SPSS, Inc., Chicago, IL, USA).
Results
Baseline parameters
Baseline characteristics are summarized in Table 1. Patients with
primary CRT implantation were younger than those receiving
CRT upgrades. The distribution of the underlying cardiomyopathy
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Table 2 Follow-up of primary cardiac resynchronization therapy recipients and upgrades
Characteristic Primary CRT CRT upgrade P-value
Time of last FUP (months after CRT implantation; mean+ SD) 21.7+14.2 23.5+15.2 0.43
D At last FUP D At last FUP
Echocardiographic parameters
LV ejection fraction (%) 10.0 (3.8–15.0) 10.0 (5.0–20.0) 0.61
End-diastolic volume (mL)a 234.0 (272.5 to 13.0) 220.0 (273 to 21.0) 0.67
End-diastolic volume index (mL/m2)a 216.0 (233.8 to 7.0) 211.0 (235.5 to 0.0) 0.55
End-systolic volume (mL)a 235.3 (275.1 to 26.9) 226.0 (278.6 to 26.1) 0.68
End-systolic volume index (mL/m2)a 217.4 (235.5 to 23.3) 214.9 (238.3 to 22.5) 0.61
LV end-diastolic diameter index (cm/m2) 20.15 (20.4 to 0.08) 20.2 (20.6 to 0) 0.66
LV end-diastolic diameter (mm) 22.0 (212.5 to 1.0) 25.0 (213.0 to 0) 0.56
LV end-systolic diameter (mm) 26.0 (213.8 to 20.25) 27.0 (216.0 to 20.75) 0.89
Left ventricular muscle mass index (g/m2)a 211 (240 to 26) 214.0 (256.5 to 9.5) 0.67
Pulmonary artery pressure (mmHg) 0 (215.3 to 8.0) 25.0 (211.0 to 1.0) 0.42
Left atrium index (cm/m2) 20.1 (20.3 to 0) 20.1 (20.2 to 0) 0.52
Change in mitral regurgitation (n, %) 0.22
Improved by two levels 3 (3) 1 (2)
Improved by one level 15 (16) 16 (28)
no change 71 (74) 38 (66)
worsened 7 (7) 3 (5)
Change in NYHA functional class (n, %) 0.51
Improved by two or more classes 4 (4) 2 (3)
Improved by one class 48 (47) 35 (50)
No change 43 (42) 30 (43)
Worsened 3 (3) 2 (3)
QRS duration (ms) 211.0 (226.5 to 14.5)b 228.0 (244.0 to 26.0)b 0.001
Pharmacological therapy at follow-up (n, %, change to baseline, n)
Beta-blockers 92 (90) 63 (90) 0.65
ACE-inhibitors 69 (68) 40 (57) 0.11
AT receptor blockers 26 (26) 25 (36) 0.18
Diuretics 81 (79) 48 (69) 0.44
Aldosterone antagonists 59 (58) 29 (41) 0.03
Aspirin 54 (53) 38 (54) 0.97
Oral anticoagulation 48 (47) 47 (67) 0.01
Number of patients (%) and median (25–75 percentile) are shown for categorical and continuous data, respectively, unless indicated otherwise. CRT, cardiac resynchronization
therapy; FUP, follow-up; NYHA, New York Heart Association; LV, left ventricular.
an ¼ 69.
bNot normally distributed.
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was similar among the two groups. Patients receiving primary CRT
implantation had higher LV end-diastolic and end-systolic diameters,
whereas end-diastolic and end-systolic volumes were similar. Atrial
fibrillation (as well as concomitant oral anticoagulation) was more
common in patients with CRT upgrade procedures. Pharmacological
heart failure therapy was optimized in both groups.
Echocardiographic and clinical follow-up
Left ventricular ejection fraction, LV end-diastolic diameter index,
and LV end-systolic diameter at baseline and at the time of last
follow-up are shown in Figure 1. Left ventricular ejection fraction
increased from 20.0 to 30.0% and from 24.0 to 35.0% in primary
CRT and in CRT upgrade recipients, respectively. Likewise, LV end-
diastolic diameter index and LV end-systolic diameter improved in
primary CRT recipients (3.5–3.2 cm/m2 and 6.0–5.2 cm, respect-
ively) and in CRT upgrade patients (3.2–3.0 cm/m2 and 5.5–
4.5 cm, respectively).
Comparison of follow-up data after primary CRT implantation
and CRT upgrade are presented in Table 2. Mean follow-up was
21.7 and 23.5 months after primary CRT implantation and CRT
upgrade, respectively. Both groups displayed a similar improvement
in LVEF, LV end-systolic and end-diastolic diameters, pulmonary
artery pressure, left atrial size, and degree of mitral regurgitation.
Improvement in NYHA functional class was equally comparable.
As expected, pre-CRT QRS duration was significantly longer in
patients with chronic RV pacing (Table 1) and was reduced more
dramatically after CRT implantation (Tables 2 and 3).
Comparison of primary CRT responders with CRT upgrade
responders are presented in Table 3. No difference in the rate of
responders, the aetiology of the underlying heart failure, or the
improvement in echocardiographic parameters was observed
between the two groups, except for a slightly more pronounced
improvement in the degree of mitral regurgitation in the CRT
upgrade group.
Responder characteristics
Baseline characteristics of responder patients receiving CRT upgrades
are summarized in Table 4, separated according to responder status.
Cardiac resynchronization therapy upgrade patients with underlying
ischaemic heart failure were less likely to respond to CRTwhen com-
pared with those with a non-ischaemic aetiology of reduced LV func-
tion.Noother baseline parameters, including underlying rhythm,QRS
duration, duration of prior RV pacing, or echocardiographic par-
ameters were distinctly predictive of response to CRT.
Baseline characteristics of responder patients receiving primary
CRT are summarized in Table 5. No baseline parameter, including
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Table 3 Follow-up parameters in cardiac resynchronization therapy responders
Characteristic Primary CRT CRT upgrade P-value
Responders, n (%) 57/102 (55.9) 39/70 (55.7) 0.98
Aetiology of heart failure 0.32
Ischaemic heart failure 20/57 (35.1) 15/39 (38.5)
Non-ischaemic heart failure 37/57 (64.9) 24/39 (61.5)
Echocardiographic parameters
D LV ejection fraction (%) 15.0 (11.5–20.5) 17.0 (13.0–22.0) 0.58
D LV end-diastolic diameter index (cm/m2) 20.3 (20.5 to 0) 20.3 (20.7 to 20.1) 0.90
D LV end-diastolic diameter (mm) 27.0 (214.0 to 21.0) 211.0 (214.5 to 22.5) 0.84
D LV systolic diameter (mm) 210 (219.8 to 23.5) 212.0 (216.0 to 23.0) 0.82
D Left atrium index (cm/m2) 20.1 (20.38 to 0) 0 (20.15 to 0.25) 0.49
Change in mitral regurgitation 0.02
Improved by two levels 0 1 (3)
Improved by one level 7 (13) 9 (28)
No change 45 (79) 22 (69)
Worsened 2 (4) 0
D Pulmonary artery pressure (mmHg) 21.0 (216.0 to 6.75) 25.5 (212.8 to 1.0) 0.31
Change in NYHA functional class (n, %) 0.18
Improved by two or more classes 3 (6) 2 (5)
Improved by one class 34 (62) 24 (63)
No change 18 (33) 28 (29)
Worsened 0 1 (3)
D QRS (ms) 26.0 (222 to 12)a 224 (243 to 26.0)a 0.02
Number of patients (%) and median (25–75 percentile) are shown for categorical and continuous data, respectively. CRT, cardiac resynchronization therapy; NYHA, New York
Heart Association; LV, left ventricular.
aNot normally distributed.
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the aetiology of heart failure, underlying rhythm, QRS duration, or
echocardiographic parameters were predictive of CRT response in
this group of patients.
Discussion
Chronic RV pacing has been shown to induce pathologic LV remo-
delling, including LV dilation and a reduction in LVEF, due to
‘extrinsically’ imposed dyssynchrony.9,11 ‘Upgrading’ these patients
to CRT to restore synchronicity may therefore be a reasonable
therapeutic option. Our data demonstrate that CRT upgrade
after chronic RV pacing results in a similar improvement in LVEF
and reduction in LV dimensions as observed in heart failure
patients after primary CRT implantation. Interestingly, our data
further indicate that CRT significantly reverses LV remodelling
even after long-term (up to 10 years) RV pacing. These results
are of particular interest as long-term survival after CRT has
been shown to be predicted by the degree of LV reverse remodel-
ling in patients undergoing primary CRT implantation.7,8
A few small-scale single centre studies have previously investi-
gated the short-term changes in LV remodelling after upgrading
chronically RV-paced heart failure patients to CRT. One study
demonstrated an acute improvement in LVEF and LV size in 15
patients upgraded to CRT.16 Similar results were observed in a
group of 20 heart failure patients with atrial fibrillation and
AV-node ablation 6 months after being upgraded to CRT.15
Although no direct comparison with primary CRT recipients was
performed in these early investigations, two more recent short-
term studies compared the effect of CRT on LV remodelling in
patients with CRT upgrade and primary CRT implantation. In the
first study, LVEF improved at least 5% in both groups after
3 months of follow-up.18 In the second very recent study, an
increase in LVEF of 13.7 and 8.7% was observed after 1-year
follow-up with primary vs. upgrade CRT implantation, respect-
ively.20 All of the above-mentioned studies, however, are limited
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Table 4 Baseline parameters of cardiac resynchronization therapy upgrade patients
Characteristic Responder Non-responder P-value
Underlying cardiomyopathy
Ischaemic 15/36 (41.7) 21/36 (58.3) 0.01
Non-ischaemic 24/34 (70.6) 10/34 (29.4)
Underlying rhythm 0.30
VAT pacing 20/33 (60.6) 13/33 (39.4)
Atrial fibrillation 19/37 (51.4) 18/37 (48.6)
QRS duration at implantation 0.57
,120 ms 1/1 (100) 0/1 (0)
121–150 5/5 (100) 0/5 (0)
151–180 ms 8/21 (38.1) 13/21 (61.9)
.180 ms 23/38 (60.5) 15/38 (39.5)
QRS (ms) 186 (163–209) 181 (174–201) 0.90
Duration of right ventricular pacing 0.74
,24 months 4/6 (66.7) 2/6 (33.3)
25–60 months 17/31 (54.8) 14/31 (45.2)
61–96 months 9/18 (50) 9/18 (50)
96–144 months 2/6 (33.3) 4/6 (66.7)
. 144 months 7/9 (77.8) 2/9 (22.2)
Duration of RV pacing 60.0 (36.0–96.0) 60.0 (48.0–85.0) 0.53
Echocardiographic parameters
LVEF at implant 25.0 (20.0–30.0) 22.0 (16.0–30.0) 0.15
,20% 8/18 (44.4) 10/18 (55.6) 0.39
20–30% 24/40 (60) 16/40 (40)
.30% 7/12 (58.3) 5/12 (41.7)
LVEDD index (cm/m2) 3.0 (2.8–3.7) 3.3 (3.0–3.5) 0.82
LVESD (mm) 50.0 (45.0–60.0) 56.0 (52.5–64.0) 0.07
Left atrium index (cm/m2) 2.6 (2.1–3.1)a 2.7 (2.3–3.1)a 0.90
Pulmonary artery pressure (mmHg) 31.0 (23.3–37.5) 30.5 (23.5–40.0) 0.67
Number of patients (%) and median (25–75 percentile) are shown for categorical and continuous data, respectively. AF, atrial fibrillation; LVEF, left ventricular ejection fraction;
LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; RV, right ventricular.
aNot normally distributed.
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by a rather low patient number, short follow-up period, and lack of
comprehensive analysis of LV remodelling. In contrast, our data
demonstrate for the first time the beneficial effect of CRT on
several parameters of LV remodelling in a large cohort of patients
receiving CRT upgrade after chronic RV pacing and show that a
similar response may be expected as after primary CRT implan-
tation. Importantly, all patients were managed by heart failure
specialists, and were maintained on optimal medical therapy both
at the time of implantation (Table 1) as well as during follow-up
(Table 2).
There is currently no gold standard for the definition of
response to CRT.21 Previous studies have frequently used com-
bined clinical and/or echocardiographic criteria to assess response
to CRT upgrade after chronic RV pacing.20,22 The use of clinical
endpoints, however, may in itself be problematic, especially in a
non-randomized, non-blinded study design. Furthermore, LV
remodelling, but not clinical improvement, is related to and may
predict long-term survival after CRT.7,8 Therefore, an absolute
increase in LVEF of ≥10% was used to define response to CRT
in our study. Using this cut-off, which in our opinion clearly
resembles a significant therapeutic effect, the rate of responders
to CRT was similar between the two groups. Furthermore, we
also observed no difference in the proportion of responders
between the two groups when using a different cut-off value
(e.g. increase in LVEF. 5%) for response (data not shown).
Of note, some differences in baseline characteristics were
observed between patients receiving primary CRT implantation
when compared with those with CRT upgrades (e.g. age, LV end-
diastolic and end-systolic diameter, rhythm at time of implan-
tation), which may have introduced a certain degree of bias in
the intergroup analyses in this non-randomized study. However,
a comparable absolute response to CRT in the intra-group ana-
lyses was observed with a similar improvement in LV reverse
remodelling. Indeed, the overall response to CRT within each
group was largely independent of the underlying rhythm, QRS dur-
ation, LVEF, LV size, and duration of prior RV pacing, indicating a
similar response potential in all subgroups of patients. In this retro-
spective analysis, LV volumes were only available in 69 patients.
There was no difference in baseline LV volumes or the improve-
ment in LV volumes between primary CRT recipients and CRT
upgrades. Together with the similar improvement in LVEF and
LV diameters between the two groups, these data strongly
suggest that CRT indeed results in a comparable degree of LV
reverse remodelling in both primary CRT and CRT upgrade
recipients.
Patients with CRT upgrades were older than those with primary
CRT implantation, and more frequently presented with atrial fibril-
lation, which is in line with previous data,20 and may be explained
by a subgroup of patients in the CRT upgrade group, who initially
underwent pacemaker implantation and AV nodal ablation due to
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Table 5 Baseline parameters of primary cardiac resynchronization therapy recipients
Characteristic Responder Non-responder P-value
Underlying cardiomyopathy 0.24
Ischaemic 20/41 (48.8) 21/41 (51.2)
Non-ischaemic 37/61 (60.7) 24/61 (39.3)
Underlying rhythm 0.38
Sinus rhythm 41/70 (58.6) 29/70 (41.4)
Atrial fibrillation 16/32 (50) 16/32 (50)
QRS duration at implantation 0.34
,120 ms 9/13 (69.2) 4/13 (30.8)
121–150 19/31 (61.3) 12/31 (38.7)
151–180 ms 14/31 (45.2) 17/31 (54.8)
.180 ms 10/17 (58.8) 7/17 (41.2)
QRS (ms) 148 (129–178) 166 (135–178) 0.24
Echocardiographic parameters
LVEF at implantation 20.0 (15.0–27.0) 23.0 (17.0–30.0) 0.63
,20% 20/36 (55.6) 16/36 (44.4) 0.99
20–30% 31/55 (56.4) 24/55 (43.6)
.30% 6/11 (54.5) 5/11 (45.5)
LVEDD index (cm/m2) 3.4 (3.0–3.9) 3.6 (3.2–3.9) 0.80
LVESD (mm) 60.0 (50.5–67.0) 61.0 (52.0–75.3) 0.15
Left atrium index (cm/m2) 2.25 (2.0–2.4)a 2.6 (2.2–2.8)a 0.01
Pulmonary artery pressure (mmHg) 31.0 (25.0–41.0) 36.0 (28.0–40.5) 0.36
Number of patients (%) and median (25–75 percentile) are shown for categorical and continuous data, respectively. AF, atrial fibrillation; LVEF, left ventricular ejection fraction;
LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter.
aNot normally distributed.
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refractory atrial fibrillation. The response to CRT, however, was
independent of the underlying rhythm both in patients receiving
CRT upgrades and after primary CRT implantation. As expected,
baseline QRS duration was longer in patients with chronic RV
pacing compared with primary CRT patients. As a consequence,
the reduction of QRS duration was more dramatic in the first
when compared with the latter group. However, response to
CRT in both groups was largely independent of baseline QRS dur-
ation, and was observed in patients both with little and with pro-
nounced conduction delay.
Patients with ischaemic cardiomyopathy receiving CRT upgrades
were less likely to respond to CRT than those with a non-
ischaemic aetiology as the cause of ventricular dysfunction. On
the other hand, patients receiving primary CRT implantation in
our cohort had a similar response rate independent of the under-
lying type of cardiomyopathy, which is somewhat in contrast to
large-scale primary CRT studies such as CARE-HF, in which the
presence of ischaemic heart disease was predictive of a worse
outcome.23 This difference may, however, be related to the echo-
cardiographic criteria used to define response to CRT in our study
(when compared with the combined clinical endpoint in
CARE-HF). Furthermore, several criteria known to affect response
such as myocardial viability or presence of myocardial scars24,25
were routinely taken into consideration before primary CRT
implantation in patients with ischaemic cardiomyopathy, and may
have resulted in a selection of patients who are more likely to
respond to CRT. In this context, a priori identification of patients
most likely to respond to CRT upgrade would be of interest. It is
conceivable that the response to CRT upgrade, similar to primary
CRT implantation, is largely influenced by the extent of scar tissue
and viable myocardium, especially in the LV pacing lead region.
However, the current study was primarily designed to investigate
whether CRT upgrade patients show evidence of LV remodelling,
and not to comprehensively assess predictors of response; hence,
further studies are required in this regard. For the time being and in
the absence of conclusive data, it is current practice of the authors
to apply the same eligibility and selection criteria for patients
receiving CRT upgrades as for primary CRT recipients.
Chronic RV pacing may induce LV remodelling and consequently
lead to worsening LV function.9–12 On an individual basis,
however, it is difficult if not impossible to discern whether a
decrease in LV function occurs as a result of RV pacing or as a con-
sequence of the natural course of the underlying cardiomyopathy.
The current study was hence not designed to address the differen-
tial contribution of these two effects to the precedent deterio-
ration of LV function but to examine the effect of CRT upgrade
on LV remodelling and compare it with primary CRT implantation.
We therefore limited our study population to patients in whom
echocardiographic follow-up was available at our centres, which
may have introduced a selection bias. For the same reason, our
study was not suited to comprehensively assess morbidity and
mortality endpoints. Very recently, a comparison of heart failure
patients undergoing CRT upgrade with primary CRT implantation
revealed a similar risk of cardiac events after a mean follow-up of
2.33 and 2.43 years, respectively.20 The mean duration of RV
pacing prior to CRT upgrade, however, was only 2.8 years in this
cohort, which is of major importance, because the detrimental
effects of RV pacing increase with increasing duration of RV
pacing.9 In contrast, the mean duration of RV pacing in our study
was 6.7 years extending up to over 12 years in nine individuals.
Interestingly, the benefit of CRT upgrade appeared independent
of the duration of previous RV pacing, and a majority of patients
even in the latter group responded to CRT. These data indicate
that reverse remodelling may occur even after very long periods
of RV pacing and hence support the use of CRT even in this
setting. As reverse LV remodelling is associated with a favourable
prognosis after primary CRT implantation,7,8 an improvement in
survival would equally be expected in this patient population.
In the current study, we only analysed the change in echocardio-
graphic parameters at the maximum follow-up time point available
for each patient, and did not perform formal longitudinal analysis of
LV remodelling after CRT implantation. We can therefore not
unequivocally prove at what time point after implantation the ben-
eficial effect of CRT upgrade begins to set in. However, when
patients with different maximum follow-up periods were com-
pared, the degree of echocardiographic improvement (as well as
in NYHA functional class) was similar at all time points investigated
(data not shown). Hence despite the lack of a formal longitudinal
analysis, our data strongly suggest that the beneficial effects of
CRT upgrade on echocardiographic reverse remodelling occur
early and are sustained, which compares well with the pattern
observed after primary CRT implantation.
In addition to the parameters investigated in the present study,
further aspects regarding the response to CRT, including the
assessment of RV size and function, diastolic dysfunction, and
echocardiographic signs of dyssynchrony may be important and
of potential interest in the comparison of primary CRT recipients
and CRT upgrades. The present retrospective study, however, was
primarily designed to assess the effect of CRT on LV function and
LV remodelling, and therefore, further studies are needed to
address these particular aspects.
Conclusions
The current study demonstrates that CRT reverses LV remodelling
in heart failure patients with chronic RV pacing in a similar way as in
primary CRT recipients, even after very long periods of RV pacing.
Our data therefore may have important implications for the treat-
ment of pacemaker-dependent patients with heart failure, and
support the use of CRT in this setting. Whether this translates
into an improved prognosis, in particular for patients with very
long-term RV pacing, remains to be determined.
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